Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis
Mattía Galli(Maria Cecilia Hospital), Dominick J. Angiolillo(University of Florida), Roxana Mehran(Mount Sinai Hospital), Francesco Franchi(Florida College), Fabiana Rollini(Florida College), Domenico D’Amario(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Renzo Laborante(Karolinska Institutet), Davide Capodanno(University of Catania), Luis Ortega‐Paz(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Charles Micheal Gibson(Beth Israel Deaconess Medical Center), Elena Tremoli(Maria Cecilia Hospital)
Cited by 62
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
2024 ESC Guidelines for the management of chronic coronary syndromes
|European Heart Journal|2024|2.3k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k